Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA
Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA
Background: The intravitreal anti-vascular endothelial growth factor treatments ranibizumab and aflibercept have proven efficacy in clinical trials, but their real world usage in central retinal vein occlusion (CRVO) has not been assessed. We therefore evaluated the treatment patterns of both drugs in a US claims database.
Methods: The IMS Integrated Data Warehouse was used to identify the patients with CRVO in the USA with claims for ranibizumab or aflibercept between 24 September 2012 and 31 March 2014 with at least 12 months follow-up. Patients were required to have had no anti-VEGF treatment code for 6 months before index (‘treatment-naive’). Mean numbers of injections and non-injection visits to a treating physician were compared with patients receiving these treatments.
Results: Patient characteristics were similar for patients receiving ranibizumab (n=206) or aflibercept (n=79) at index. The mean (±SD) numbers of injections received by patients treated with ranibizumab or aflibercept were 4.4±2.8 and 4.7±2.9 (P=0.38), respectively; the total number of patient visits to their treating physician was 7.3±3.7 and 7.0±2.9 (P=0.52), respectively. For patients receiving one or more injections (n=238), the mean interval between injections was 55.1 days (ranibizumab) and 54.2 days (aflibercept; P=0.44).
Conclusions: Our results suggest that, in routine clinical practice, patients receive a comparable number of injections in the first year of treatment with ranibizumab or aflibercept. This may have implications for commissioning and service development of CRVO care pathways.
380-387
Lotery, A.J.
5ecc2d2d-d0b4-468f-ad2c-df7156f8e514
Regnier, S.
3f10257e-8ea4-4c80-ab4a-d54824c0605a
29 March 2015
Lotery, A.J.
5ecc2d2d-d0b4-468f-ad2c-df7156f8e514
Regnier, S.
3f10257e-8ea4-4c80-ab4a-d54824c0605a
Lotery, A.J. and Regnier, S.
(2015)
Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA.
Eye, 29 (3), .
(doi:10.1038/eye.2014.308).
(PMID:25572584)
Abstract
Background: The intravitreal anti-vascular endothelial growth factor treatments ranibizumab and aflibercept have proven efficacy in clinical trials, but their real world usage in central retinal vein occlusion (CRVO) has not been assessed. We therefore evaluated the treatment patterns of both drugs in a US claims database.
Methods: The IMS Integrated Data Warehouse was used to identify the patients with CRVO in the USA with claims for ranibizumab or aflibercept between 24 September 2012 and 31 March 2014 with at least 12 months follow-up. Patients were required to have had no anti-VEGF treatment code for 6 months before index (‘treatment-naive’). Mean numbers of injections and non-injection visits to a treating physician were compared with patients receiving these treatments.
Results: Patient characteristics were similar for patients receiving ranibizumab (n=206) or aflibercept (n=79) at index. The mean (±SD) numbers of injections received by patients treated with ranibizumab or aflibercept were 4.4±2.8 and 4.7±2.9 (P=0.38), respectively; the total number of patient visits to their treating physician was 7.3±3.7 and 7.0±2.9 (P=0.52), respectively. For patients receiving one or more injections (n=238), the mean interval between injections was 55.1 days (ranibizumab) and 54.2 days (aflibercept; P=0.44).
Conclusions: Our results suggest that, in routine clinical practice, patients receive a comparable number of injections in the first year of treatment with ranibizumab or aflibercept. This may have implications for commissioning and service development of CRVO care pathways.
Text
eye2014308a.pdf
- Version of Record
Available under License Other.
More information
Accepted/In Press date: 25 November 2014
e-pub ahead of print date: 9 January 2015
Published date: 29 March 2015
Organisations:
Faculty of Medicine
Identifiers
Local EPrints ID: 390420
URI: http://eprints.soton.ac.uk/id/eprint/390420
ISSN: 0950-222X
PURE UUID: 06e1fc3d-80e0-4e95-8252-fe59b30d8f33
Catalogue record
Date deposited: 01 Apr 2016 13:11
Last modified: 15 Mar 2024 03:16
Export record
Altmetrics
Contributors
Author:
S. Regnier
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics